Patient-derived xenograft (PDX) models, in which tumor tissues from patients are implanted
into immunocompromised or humanized mice, have shown superiority in recapitulating the …

Patient-derived xenografts (PDXs) have emerged as an important platform to elucidate new
treatments and biomarkers in oncology. PDX models are used to address clinically relevant …

Abstract Although 5-methylcytosine (m5C) is a widespread modification in RNAs, its
regulation and biological role in pathological conditions (such as cancer) remain unknown …

Adoptive T cell therapy (ACT) produces durable responses in some cancer patients;
however, most tumors are refractory to ACT and the molecular mechanisms underlying …

Cancer was thought to be caused solely by genetic mutations in oncogenes and tumor
suppressor genes. In the last 35 years, however, epigenetic changes have been …

Colorectal cancer (CRC), despite the advances in screening and surveillance, remains the
second most common cause of cancer death worldwide. The biological inadequacy of pre …

Epigenetic mechanisms are central to understanding the molecular basis underlying
tumorigenesis. Aberrations in epigenetic modifiers alter epigenomic landscapes and play a …

Malignant melanoma is the most deadly form of skin cancer. It originates from melanocytic
cells and can also arise at other body sites. Early diagnosis and appropriate medical care …

Cutaneous melanoma is a lethal disease, even when diagnosed in advanced stages.
Although recent progress in biology and treatment has dramatically improved survival rates …

Precision oncology research is challenging outside the contexts of oncogenic addiction
and/or targeted therapies. We previously showed that phosphoproteomics is a powerful …